OncoMatch/Clinical Trials/NCT05553782
Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers
Is NCT05553782 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies Implantable Microdevice (IMD) for salivary gland cancer.
Treatment: Implantable Microdevice (IMD) — This research study is studying the effect of different drugs as possible treatments for salivary and other head and neck cancers/ The name of the study intervention involved in this study is: \-- implantable microdevice
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Excluded: Stage IV, ADVANCED, INCURABLE
without evidence of recurrent, metastatic or advanced, incurable disease undergoing definitive surgical management; any stage disease is permitted (American Joint Committee on Cancer 2017 8th edition)
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
platelet count ≥50,000/mcl, pt/inr <2, and aptt <1.5x upper limit of normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Brigham and Women's Hospital · Boston, Massachusetts
- Dana Farber Cancer Institute · Boston, Massachusetts
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05553782 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages